Latest Insider Transactions at Entrada Therapeutics, Inc. (TRDA)
This section provides a real-time view of insider transactions for Entrada Therapeutics, Inc. (TRDA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Entrada Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Entrada Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 20
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
16,849
+0.21%
|
$84,245
$5.84 P/Share
|
May 18
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
34,433
+0.43%
|
$172,165
$5.96 P/Share
|
May 17
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
18,511
+0.47%
|
$111,066
$6.13 P/Share
|
May 16
2022
|
Baker Bros. Advisors LP |
BUY
Open market or private purchase
|
Indirect |
19,000
+0.49%
|
$95,000
$5.83 P/Share
|
Mar 01
2022
|
Dipal Doshi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
30,250
+12.35%
|
-
|
Mar 01
2022
|
Kory James Wentworth Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,006
+34.89%
|
-
|
Mar 01
2022
|
Nerissa Kreher Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,344
+39.96%
|
-
|
Mar 01
2022
|
Natarajan Sethuraman President, Research & Develop. |
BUY
Grant, award, or other acquisition
|
Direct |
11,588
+6.9%
|
-
|
Mar 01
2022
|
Nathan J Dowden President & COO |
BUY
Grant, award, or other acquisition
|
Direct |
11,263
+13.43%
|
-
|
Jan 13
2022
|
Dipal Doshi CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+5.14%
|
$10,000
$1.74 P/Share
|
Jan 12
2022
|
John F Crowley Director |
BUY
Open market or private purchase
|
Direct |
5,000
+50.0%
|
$45,000
$9.71 P/Share
|
Dec 29
2021
|
Nerissa Kreher Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+50.0%
|
$10,400
$2.1 P/Share
|
Nov 02
2021
|
Kush Parmar |
BUY
Open market or private purchase
|
Indirect |
250,000
+18.09%
|
$5,000,000
$20.0 P/Share
|
Nov 02
2021
|
Kush Parmar |
BUY
Conversion of derivative security
|
Indirect |
3,827,224
+32.12%
|
-
|
Nov 02
2021
|
Todd Foley Director |
BUY
Open market or private purchase
|
Indirect |
100,000
+2.21%
|
$2,000,000
$20.0 P/Share
|
Nov 02
2021
|
Todd Foley Director |
BUY
Conversion of derivative security
|
Indirect |
4,325,784
+30.26%
|
-
|
Nov 02
2021
|
Mpm Bio Ventures 2014, L.P. |
BUY
Open market or private purchase
|
Indirect |
100,000
+2.21%
|
$2,000,000
$20.0 P/Share
|
Nov 02
2021
|
Mpm Bio Ventures 2014, L.P. |
BUY
Conversion of derivative security
|
Indirect |
4,325,784
+30.26%
|
-
|
Nov 02
2021
|
Mpm Bioventures 2018, L.P. |
BUY
Open market or private purchase
|
Indirect |
100,000
+2.21%
|
$2,000,000
$20.0 P/Share
|
Nov 02
2021
|
Mpm Bioventures 2018, L.P. |
BUY
Conversion of derivative security
|
Indirect |
4,325,784
+30.26%
|
-
|
Nov 02
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+33.85%
|
$20,000,000
$20.0 P/Share
|
Nov 02
2021
|
Redmile Group, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
954,420
+50.0%
|
-
|
Nov 02
2021
|
5 Am Ventures V, L.P. |
BUY
Open market or private purchase
|
Indirect |
250,000
+18.09%
|
$5,000,000
$20.0 P/Share
|
Nov 02
2021
|
5 Am Ventures V, L.P. |
BUY
Conversion of derivative security
|
Indirect |
3,827,224
+32.12%
|
-
|
Nov 02
2021
|
Roche Holding LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
2,813,525
+30.08%
|
-
|